NCCN Guidelines® Insights - Gastric Cancer, Version 1.2013
The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence and consensus based recommendations for a multidisciplinary approach for the management of patients with gastric cancer. For patients with resectable locoregional cancer, the guidelines recommend gastrectomy with a D1+ or a modified D2 lymph node dissection (performed by experienced surgeons in high-volume centers). Postoperative chemoradiation is the preferred option after complete gastric resection for patients with T3–T4 tumors and node-positive T1–T2 tumors. Postoperative chemotherapy is included as an option after a modified D2 lymph node dissection for this group of patients. Trastuzumab with chemotherapy is recommended as first-line therapy for patients with HER2-positive advanced or metastatic cancer, confirmed by immunohistochemistry and, if needed, by fluorescence in situ hybridization for IHC 2+.
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to NCCN Guidelines for gastric cancer
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for gastric cancer
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician